Pharmaceutical giant GlaxoSmithKline (GSK) has reported better-than-expected fourth-quarter results, exceeding market estimates. The company has also expressed optimism about its growth prospects for the year 2024.
GSK's fourth-quarter revenue reached $11.8 billion, a 1% increase compared to the same period last year. Analysts had estimated a revenue of $11.56 billion, making the actual figures a positive surprise. The growth was mainly driven by strong sales in the company's pharmaceuticals division, which saw a 4% increase in revenue.
